OncoDNA, SOLTI Agreement to Provide Molecular Profile Analysis
News Oct 27, 2016
Belgium-based OncoDNA SA, The Cancer Theranostic Company, which supplies the only comprehensive solution from cancer profiling (OncoDEEP&TRACE), combining solid and liquid biopsies analysis to help oncologists with drug treatment options and efficacy monitoring, has signed a partnership agreement, through its Spanish distributor BioSequence, with SOLTI, a non-profit organization dedicated to clinical research in breast cancer with a broad network of leading hospital centers in Spain, Portugal, France and Italy to supply tumor molecular profiling analysis for SOLTI’s AGATA breast cancer screening program.
AGATA, the pilot trial of a genomic screening program pioneered in Spain, aims to refer breast cancer patients to clinical trials based on their molecular profile. With this partnership, SOLTI takes advantage of OncoDNA’s solid experience in data processing to streamline and customize patient data collection.
“This collaboration is a great opportunity to exchange knowledge and know-how between OncoDNA and SOLTI, both organizations focused on improving cancer patient care. We are excited to work together to enhance the outcomes we provide through the AGATA program to better direct patients to clinical trials according to their tumor profile,” said Dr. Eva Ciruelos, President of SOLTI.
Jean-François Laes, CTO of OncoDNA, said: “We are happy that the first OncoKDM collaboration we can announce publicly is with this renowned SOLTI breast cancer group. Our goal when we developed OncoKDM was to propose access to our database and share our expertise. This project gathering molecular data from different technology and geographical origins illustrates the advantage of a centralized, harmonized and expert oncology system to improve cancer patient care.”
About 422 million people around the world, including more than 30 million Americans, have diabetes. Obesity is the most significant risk factor for type 2 diabetes. yet about 30 percent of obese people do not develop type 2 diabetes or other metabolic conditions. New research aims to understand on a cellular level, how this separation occurs.READ MORE
Habitat loss, habitat fragmentation and the loss of genetic diversity are the main factors driving the extinction of many wild species, and the few eastern massasauga rattlesnakes remaining in Illinois have certainly suffered two of the three. A long-term study of these snakes reveals, however, that – despite their alarming decline in numbers – they have retained a surprising amount of genetic diversity.READ MORE